Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T01:40:13.689Z Has data issue: false hasContentIssue false

Ferrous sulphate does not directly affect pteroylmonoglutamic acid absorption in rats

Published online by Cambridge University Press:  09 March 2007

Norman R. C. Campbell
Affiliation:
Divisions of Geriatrics and Internal Medicine, Departments of Medicine and Pharmacology and Therapeutics, Faculty of Medicine, The University of Calgary, Calgary, Alberta, CanadaT2N 4NI
Brian B. Hasinoff
Affiliation:
Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3T 2N2
Mukhtiar Slngh
Affiliation:
Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3T 2N2
Susan Robertson
Affiliation:
Divisions of Geriatrics and Internal Medicine, Departments of Medicine and Pharmacology and Therapeutics, Faculty of Medicine, The University of Calgary, Calgary, Alberta, CanadaT2N 4NI
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A variety of compounds which bind to Fe have substantial reductions in absorption when co-administered with Fe compounds. The binding of both Fe2+ and Fe3+ ions to pteroylmonoglutamic acid and the pteroylmonoglutamate dianion was examined in vitro. In dimethylsulphoxide (DMSO) alone, pteroylmonoglutamate formed a 2:1 (pteroylmonoglutamate: Fe3+ ion) complex. However, in DMSO–aqueous Bis-Tris buffer (4:1, v/v; pH 6.0) no evidence of complex formation could be seen. Likewise spectroscopic evidence was obtained for complex formation with Fe2+ ion and pteroylmonoglutamate in DMSO alone but not in the aqueous DMSO buffer. In vivo studies examined the effect of FeSO4 on pteroylmonoglutamic acid absorption in an isolated perfused rat jejunal model of nutrient absorption. The dose of pteroylmonoglutamic acid approximated a human dose of 1 mg for the rat, while the FeSO4 doses were chosen to represent 6.4 mg, 64 mg and 300 mg human doses. There was no significant effect of FeSO4 on pteroylmonoglutamic acid absorption or instability of pteroylmonoglutamic acid in vivo in the presence of FeSO4 in the rat. Although 2:1 binding of pteroylmonoglutamic acid to Fe ions could be demonstrated in DMSO alone, no binding could be demonstrated in DMSO–Bis-Tris buffer (4:1, v/v; pH 6.0). It is unlikely that there will be a significant reduction in pteroylmonoglutamic acid absorption during concurrent ingestion of Fe preparations.

Type
Interactions in the absorption of folic acid
Copyright
Copyright © The Nutrition Society 1994

References

REFERENCES

Albert, R. A. (1953). Quantitative studies of the avidity of naturally occurring substances for trace metals. Biochemical Journal 54, 646654.CrossRefGoogle ScholarPubMed
Campbell, N. R. C. & Hasinoff, B. B. (1991). Iron supplements: a common cause of drug interactions. British Journal of Clinical Pharmacology 31, 251255.CrossRefGoogle ScholarPubMed
Campbell, N. R. C., Hasinoff, B. B., Meddings, J. B., Anderson, W. B., Robertson, S. & Granberg, K. (1993 a). Ferrous sulfate reduces cimetidine absorption. Digestive Diseases and Sciences 38, 950954.CrossRefGoogle ScholarPubMed
Campbell, N. R. C., Hasinoff, B. B., Robertson, S. & Singh, M. (1993 b). Absence of an effect of ferrous sulfate on phenytoin absorption. Clinical and Investigative Medicine 16, 280284.Google ScholarPubMed
Campbell, N. R. C., Hasinoff, B. B., Stalts, H., Rao, B. & Wong, N. (1992 a). Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Annals of Internal Medicine 117, 10101013.CrossRefGoogle ScholarPubMed
Campbell, N. R. C., Kara, M., Hasinoff, B. & McKay, D. W. (1992 b). Norfloxacin interaction with antacids and minerals. British Journal of Clinical Pharmacology 33, 115116.CrossRefGoogle Scholar
Canadian Pharmaceutical Association (1992). Compendium of Pharmaceuticals and Specialties, 27th ed. [Krogh, C. M. E., editor]. Ottawa: Canadian Pharmaceutical Association.Google Scholar
Cape, J. N., Cook, D. H. & Williams, D. R. (1974). Thermodynamic considerations in co-ordination. Part XIX. In vitro studies of complexing equilibria involved in oral iron (11) therapy. Journal of the Chemistry Society (Dalton Trans) 18491852.Google Scholar
Czeizel, A. E. & Dudas, I. (1992). Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. New England Journal of Medicine 327, 18321835.CrossRefGoogle ScholarPubMed
Hillman, R. S. (1990). Drugs effective in iron-deficiency and other hypochromic anemias. In Goodman and Gillman's The Pharmacological Basis of Therapeutics, 8th ed., pp. 12771310 [Gilman, A. G., Rall, T. W., Nies, A. S. and Taylor, P., editors]. New York: Pergamon Press.Google Scholar
La Piana Simonsen, L. (1990). Top two hundred drugs of 1989. Pharmacy Times 56, 5644.Google Scholar
Meddings, J. D. & Westergaard, H. (1989). Intestinal glucose transport using perfused rat jejunum in vivo: model analysis and derivation of corrected kinetic constants. Clinical Science 76, 104113.CrossRefGoogle ScholarPubMed
Partlow, E., Chan, S. C., Pap, K. M. & Campbell, N. R. C. (1993). The effect of ferrous sulfate on cimetidine absorption in healthy volunteers. Clinical Pharmacology and Therapeutics 53, 163 (Abstr).Google Scholar
Roos, J. T. H. & Williams, D. R. (1977). Formation constants for citrate-, folid acid-, gluconate-, and succinate- proton, -manganese (11) and -zinc (11) systems: relevance to absorption of dietary manganese, zinc and iron. Journal of Inorganic and Nuclear Chemistry 39, 361369.CrossRefGoogle Scholar
Rosenberg, I. H. (1992). Folic acid and neural tube defects -time for action? New England Journal of Medicine 327, 18751876.CrossRefGoogle ScholarPubMed
Vitale, J. J., Restrepo, A., Velez, H., Riker, J. B. & Hellerstein, E. E. (1966). Secondary folate deficiency induced in the rat by dietary iron deficiency. Journal of Nutrition 88, 315322.CrossRefGoogle ScholarPubMed